PROM1 Antibody
- Known as:
- PROM1 Antibody
- Catalog number:
- abx000605
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- PROM1 Antibody
Related genes to: PROM1 Antibody
- Gene:
- PROM1 NIH gene
- Name:
- prominin 1
- Previous symbol:
- PROML1, MCDR2, STGD4
- Synonyms:
- AC133, CD133, RP41, CORD12
- Chromosome:
- 4p15.32
- Locus Type:
- gene with protein product
- Date approved:
- 1999-04-15
- Date modifiied:
- 2016-10-05
Related products to: PROM1 Antibody
Related articles to: PROM1 Antibody
- Breast cancer is the foremost cause of cancer-related death in women globally, and taxane-anthracycline (TA) combination regimens represent standard frontline chemotherapy. Although widely administered, the pathological complete response rate to TA therapy is less than 30%, and chemoresistance remains a major barrier to effective disease control, frequently leading to relapse and poor survival. Both metabolic reprogramming and tumor microenvironmental remodeling are closely associated with treatment failure, yet how they interact to drive TA resistance remains largely unclear. Here we show that phosphofructokinase platelet (PFKP), a key glycolytic enzyme, is highly expressed in breast cancer. PFKP drives glycolysis and promotes CD133 cancer stem-like cells (CSLCs) that are inherently TA-resistant. Moreover, PFKP-overexpressing cancer cells stimulate cancer-associated fibroblasts (CAFs), which in turn augment CD133 CSLC formation via the CXCL16/CXCR6 axis, establishing a feedforward loop that reinforces chemoresistance. These results reveal a previously unappreciated mechanism by which a glycolytic enzyme in cancer cells orchestrates stromal crosstalk to sustain a chemotherapy-refractory niche. By identifying PFKP as a key driver and the PFKP-CSLC-CAF axis as an actionable target, our work moves the field beyond the traditional view of metabolic reprogramming as a cell-autonomous event. Disrupting this axis-for instance, by PFKP inhibition or CXCL16/CXCR6 blockade-may restore TA sensitivity in aggressive basal-type breast cancer, offering a promising strategy to improve long-term outcomes for hard-to-treat patients. - Source: PubMed
Publication date: 2026/04/23
Fang KaiMa YueLi LihuaYue YanRuan HangXiong Sidong - Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that a section of the western blot image for β‑actin in Fig. 1B on p. 157 had also been used for the control β‑actin blots in Fig. 3C on p. 159, despite these data having come from different sources (Fig. 1: CD133 ovarian cancer cells compared with Fig. 3: CD133 ovarian cancer stem cells infected with recombinant adenovirus). In addition, upon performing an independent analysis of the data in this paper in the Editorial Office, it also came to light that, regarding the TUNEL assay experiments shown in Figs. 2 and 4, the data shown for panel '1' in Fig. 2D was strikingly similar to that shown for the 'Blank' panel in Fig. 4C, even though the experimental conditions in these figures were reported to be different. The authors have been contacted by the Editorial Office to offer an explanation for this apparent duplication of data within these figures, and we are waiting their response. Owing to the fact that the Editorial Office has been made aware of potential issues surrounding the scientific integrity of this paper, we are issuing an Expression of Concern to notify readers of these potential problems while the Editorial Office continues to investigate this matter further. [Oncology Reports 37: 155‑162, 2017; DOI: 10.3892/or.2016.5263]. - Source: PubMed
Publication date: 2026/04/17
Long QifangYang RuLu WeixianZhu WeipeiZhou JundongZheng CuiZhou DongmeiYu LingWu Jinchang - Mesenchymal stromal cells (MSCs) are widely used in human cell-based therapies and recent research is focused on the use of MSCs in equine regenerative medicine. Recently, MSCs have been isolated from equine follicular aspirates; however, a major concern during isolation is the potential contamination with fibroblasts, the predominant stromal cell type in many tissues. Furthermore, both cell types share the minimal criteria established by the International Society for Cellular Therapy (ISCT) for MSCs identification. Hence, our study aimed to compare the morphological characteristics, expansion behavior, immunophenotype, differentiation capacity and gene expression profiles of equine MSCs obtained from follicular aspirates and a commercial equine dermal fibroblast cell line. Under standard culture conditions, both cell lines exhibited a spindle-like morphology, expressed mesenchymal markers such as CD90 or CD29, and lacked the expression of CD45, CD19 and MHC-II, and manifested trilineage differentiation, however the chondrogenic differentiation was less evident in fibroblasts. Transcriptomic analysis using an RT² Profiler PCR Array revealed 35 differentially expressed genes between MSCs and fibroblasts. These results were further validated by quantitative PCR analysis: while fibroblasts showed higher expression of ANPEP, PROM1 and SOX2, genes like FGF2, LIF and KDR were downregulated in these cells. Moreover, GDF6, a key factor for MSCs differentiation, was markedly downregulated in fibroblasts. In conclusion, our results demonstrate that conventional criteria, including morphology, immunophenotyping, differentiation assays, and gene expression analysis, are insufficient to unequivocally identify MSCs. These findings underscore the need to implement additional experimental approaches to confidently discriminate between MSCs and fibroblasts. - Source: PubMed
Publication date: 2026/04/02
Del Prado Soriano-Campos MaríaMuñoz-García Carmen CristinaLuis-Calero MarcosGallardo-Soler AlejandroGonzález-Fernández LauroMacías-García Beatriz - Glioblastoma or grade IV glioma is characterized by extremely poor prognosis. Resistance to radio- / chemotherapy and recurrences are associated with tumor stem cells. Transmembrane protein CD133 is considered a potential marker of tumor stem cells. To overcome the limitations of detecting cellular CD133 by antibodies, potential of aptamers (nucleic acid-based molecular recognition elements) is being explored. To obtain reproducible results, it is necessary to study the interaction of fluorescent aptamers to CD133 with standard cell lines and cell cultures derived from patient tumors using various methods. - Source: PubMed
Ivko V LMakeeva V EAntipova O MSavchenko E APronin I NPavlova G VKopylov A M - Cancer stem cells (CSC) can sustain tumor growth and therapeutic resistance in part through their contribution to vasculogenic mimicry (VM) in ovarian cancers. Pharmacological targeting of CSC-associated transcriptional programs could represent a promising strategy to overcome recurrence and metastasis. While preclinical studies show caffeic acid phenethyl ester (CAPE), a plant-derived metabolite, can sensitize tumors to chemotherapy and radiotherapy, little is known about its anti-VM properties. - Source: PubMed
Publication date: 2026/03/17
Touaibia MohamedBoudah AnesZgheib AlainDanalache Bogdan AlexandruAnnabi Borhane